目的 探究清肝利膽口服液聯(lián)合腺苷蛋氨酸治療新生兒肝內(nèi)膽汁淤積癥的效果。方法 選取2015年9月—2018年9月鄭州市婦幼保健院收治的肝內(nèi)膽汁淤積新生兒98例作為研究對象，采用隨機數(shù)字表法將患兒分為對照組和觀察組，每組各49例。對照組靜脈滴注注射用丁二磺酸腺苷蛋氨酸，30～60 mg/（kg·d）。觀察組在對照組的基礎(chǔ)上給予清肝利膽口服液，3～5 mL/次，3次/d。兩組均連續(xù)治療15 d。比較兩組患者的臨床療效，同時比較兩組患者的肝功能相關(guān)指標和不良反應(yīng)發(fā)生情況。結(jié)果 治療后，觀察組總有效率為95.92%，顯著高于對照組的81.63%（P<0.05）。治療后，兩組谷丙轉(zhuǎn)氨酶（ALT）、總膽紅素（TBIL）和直接膽紅素（DBIL）水平均顯著下降（P<0.05）；治療后，觀察組肝功能指標水平顯著低于對照組（P<0.05）。兩組患兒不良反應(yīng)發(fā)生率比較差異無統(tǒng)計學意義。結(jié)論 清肝利膽口服液聯(lián)合腺苷蛋氨酸可顯著改善肝內(nèi)膽汁淤積癥患兒的肝功能，提高治療效果，且不增加不良反應(yīng)發(fā)生率，值得臨床借鑒。

Objective To explore the effect of Qinggan Lidan Oral Liquid combined with ademetionine in treatment of neonatal intrahepatic cholestasis. Methods A total of 98 children with neonatal intrahepatic cholestasis in Women & Infants Hospital of Zhengzhou from September 2015 to September 2018 were selected as the research objects, and the children were divided into control group and observation group by random number table method, with 49 cases in each group. Children in the control group were iv administered with Ademetionine 1,4-Butanedisulfonate for Injection for 30-60 mg/(kg·d). Children in the observation group was given Qinggan Lidan Oral Liquid on the basis of the control group, 3-5mL/time, and three times daily. Both groups received continuous treatment for 15 days. The clinical efficacy of two groups was compared, and the indicators related to liver function and the occurrence of adverse reactions were also compared between two groups. Results After treatment, the total effective rate of the observation group was 95.92%, significantly higher than 81.63% of the control group (P<0.05). After treatment, ALT, TBIL and DBIL levels were decreased significantly (P<0.05). After treatment, the liver function index level of the observation group was significantly lower than that of the control group (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups. Conclusion Qinggan Lidan Oral Liquid combined with ademetionine can significantly improve the liver function of children with intrahepatic cholestasis, improve the treatment effect, and do not increase the incidence of adverse reactions, which is worthy of clinical reference.

R975